"Seizing Emerging Opportunities in Medical Innovation"

This year’s Investors Conference dedicated specifically to Regenerative Medicine and cell based technologies and therapies will be held as an all day event in October or November, 2010.

Cell based therapies are directed to develop technologies and treatments in indications such as cardio-vascular diseases (MI and stroke); neurodegenerative disorders (Parkinson’s); organ repair (liver); Diabetes; and various Cancers. The Conference is geared primarily towards institutional and strategic investors interested to understand opportunities for financial participation in this fast emerging innovative field of medicine. The topics of this year’s Conference will not only offer potential investors a showcase of interesting projects but also address issues surrounding the research and technologies in question. This innovative new field of modern medicine has experienced tremendous progress throughout the last year and the opportunities are beginning to take visible shape.

Press Conference

• Chair: Mrs. Ulrike Schwemmer, GRM President

Welcome Remarks

• Prof. Konrad Kohler, GRM Board of Directors

Political Key Note Address

• (TBA)

Introduction

• Modern Use of Stem Cells: Focus in Clinical Practice
  Prof. Dr. med. Matthias Schieker

Legal Presentations

• Chair: Andreas Nitsch, Esq., GRM Board of Directors
  
  
• "The Ethics of Patenting Human Stem Cells"
  Alan J. Morrison
  Cohen Pontani Lieberman & Pavane LLP
  New York, USA
  
  
• Intellectual Property of Human Stem Cells
  Within Current Legal Parameters
  Dr. Ulrich Storz
  Kanzlei Michalski Huettermann & Partner
  Düsseldorf, Germany
  
  
• "Critical Commercial and Partnering Issues for
  Stem Cells and Related Technologies"
  Dr. Alexander Oehmichen, Esq.
  Dr. Oehmichen & Partner Rechtsanwälte
  Bad Vilbel, Germany

Industrial Presentations

• Chair: Christian Scheiner, Chairman D42C
  
  
• Magnetic Cell Sorting (MACS): A Platform Technology for Cellular Therapies
  Dr. Kai Pinkernell, Head of Clinical Development
  Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
  
  
• (TBA)
  Wolfgang Kintzel, Chief Marketing and Sales Officer
  CEVEC Pharmaceuticals GmbH, Cologne, Germany
  
  
  

Biomedical Presentations

• Chair: Prof. Guido Nikkhah, GRM Scientific Spokesperson
  
  
  

The speaker(s) will be announced shortly. The key note will focus on the establishment of a government sponsored Fund providing financial support for the validation of technologies to proof of principle. In order to gain access to sources of funding, researchers and start-ups need to show proof of principle for their innovative technologies. Reaching proof of principle stage is currently a great financial challenge and the German government promised to advance promising technologies through establishment of this Fund earmarked specifically for proof of principle research.

There will be a total of three Legal Presentations addressing ethical, IP and contractual issues related to stem cells and cell based technologies. The Industrial Presentations will feature medium and larger size companies involved in regenerative medicine projects and will describe the particular interests of these companies in the emerging technologies. Finally, the Biotechnology Presentations will feature presentations of specific projects in pre start-up or early start-up stage from selected clusters of excellence in Regenerative Medicine.

The titles along with the presenters are currently being finalized and will be announced shortly.

Please visit this Conference website at www.regmedinvest.com for the most up-to-date information!